Histone deacetylase inhibitors, which are in clinical use as anticancer agents, also affect the biology of regulatory T cells. These inhibitors may also hold promise as immunomodulatory drugs (pages 1299–1307).
References
Zheng, Y. & Rudensky, A.Y. Nat. Immunol. 8, 457–462 (2007).
Bluestone, J.A. Nat. Rev. Immunol. 5, 343–349 (2005).
Tao, R., et al. Nat. Med. 13, 1305–1313 (2007).
Bolden, J.E., Peart, M.J. & Johnstone, R.W. Nat. Rev. Drug Discov. 5, 769–784 (2006).
Leoni, F. et al. Proc. Natl. Acad. Sci. USA 99, 2995–3000 (2002).
Mishra, N., Reilly, C.M., Brown, D.R., Ruiz, P. & Gilkeson, G.S. J. Clin. Invest. 111, 539–552 (2003).
Reddy, P. et al. Proc. Natl. Acad. Sci. USA 101, 3921–3926 (2004).
Chen, C., Rowell, E.A., Thomas, R.M., Hancock, W.W. & Wells, A.D. J. Biol. Chem. 281, 36828–36834 (2006).
Floess, S. et al. PLoS Biol. 5, e38 (2007).
Zheng, Y. et al. Nature 445, 936–940 (2007).
Wu, Y. et al. Cell 126, 375–387 (2006).
Ono, M. et al. Nature 446, 685–689 (2007).
Li, B. et al. Proc. Natl. Acad. Sci. USA 104, 4571–4576 (2007).
Allan, S.E. et al. J. Clin. Invest. 115, 3276–3284 (2005).
Brogdon, J.L. et al. Blood 109, 1123–1130 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reddy, P., Zou, W. Blocking HDACs boosts regulatory T cells. Nat Med 13, 1282–1284 (2007). https://doi.org/10.1038/nm1107-1282
Issue Date:
DOI: https://doi.org/10.1038/nm1107-1282
- Springer Nature America, Inc.